Skip to search formSkip to main contentSkip to account menu
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
TLDR
Analysis of the HIV protease gene from the plasma of HIV–infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitors ritonavir, suggesting that dual protease inhibitor therapy might increase the duration of viral suppression.
View on Springer
Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
TLDR
A database containing information about the clearance routes for over 300 drugs from multiple therapeutic classes, including analgesics, anti-infectives, psychotropics, anticonvulsants, cancer chemotherapeutics, gastrointestinal agents, cardiovascular agents and others, was constructed to assist in the semiquantitative prediction of the magnitude of potential interactions with drugs under development.
View on Springer
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
TLDR
Combination regimens of ritonavir and other protease inhibitors may thus play a role in the treatment of HIV infection, however, such combinations require further investigation to establish safe regimens for clinical use.
View on ASMUSA
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
TLDR
The large increase in the plasma concentrations of other protease inhibitors when coadministered with ritonavir forms the basis of rational dual protease inhibitor regimens, providing patients with 2 potent drugs at significantly reduced doses and less frequent dosage intervals.
View on PubMed
Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
TLDR
The combination of ABT-378 and ritonavir was much weaker in inhibiting CYP-mediated biotransformations than ritonivir alone, and the inhibitory effect appears to be primarily due to the ritonvir component of the combination.
View on PubMed
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
TLDR
The potential utility of ABT-378 as a therapeutic intervention against AIDS is demonstrated by using the X-ray crystal structure of the complex of HIV protease and ritonavir to design a potent protease inhibitor which has a diminished interaction with Val 82.
View on ASMUSA
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant…
View on PubMed
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
TLDR
Constant concentration-dependent autoinduction is the most likely mechanism for the time-dependent pharmacokinetics of ritonavir, and the levels were correlated with baseline triglyceride levels and AUC, Cmax, or predose concentrations.
View on ASMUSA
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir *
View on Wiley
Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers
TLDR
With the altered pharmacokinetic profile, indinavir likely could be given as a b.i.d. combination regimen with ritonavir to improve patient compliance and thereby reduce treatment failures.
View on ASMUSA
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License